Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|June 2, 2017
- Pharmaceutical Technology-06-02-2017
- Volume 41
- Issue 6
Sterilizer Uses Pulsed Light Technology
The Robotic Pulsed Light Sterilizer (RPLS1) from Steriline uses pulsed light technology for ready-to-use nest sterilization and can sterilize tubs of syringes, vials, and cartridges.
The Robotic Pulsed Light Sterilizer (RPLS1) from Steriline uses pulsed light technology for ready-to-use nest sterilization and can sterilize tubs of syringes, vials, and cartridges. The RPLS1 has a processing capacity of up to 120 tubs per hour. The machine is automatically sterilized by vapor of hydrogen peroxide before the start of production. The RPLS1 can be connected to any ready-to-use nest filling machine and is able to connect to machines that are enclosed in isolators.
Articles in this issue
over 9 years ago
Control Box Connects Lab Sensors and Pumpsover 9 years ago
Planetary Dispersers with PLC Recipe Controlsover 9 years ago
Paperless Recorder Shortens Sampling Intervalsover 9 years ago
Boosting Bioproduction Workflows with Automation Technologiesover 9 years ago
Decoding Serialization Regulationsover 9 years ago
Synchronizing Anticounterfeiting Effortsover 9 years ago
New and Updated Laboratory Equipment Optimize Efficiencyover 9 years ago
Understanding Dissolution Testingover 9 years ago
Particle Size Reduction for Investigational New DrugsRelated to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.